Trial Profile

Phase II Study Of Preoperative Chemoradiotherapy Plus Avelumab In Patients With Locally Advanced Rectal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Capecitabine
Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
Focus Therapeutic Use
Acronyms AVANA

Most Recent Events

02 Jun 2026 Primary endpoint (The primary objective of this trial is to evaluate the rate of complete pathologic response (pCR)) has been met as per results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
18 Oct 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com